The MDM2 SNP309T>G Polymorphism Increases Bladder Cancer Risk among Caucasians: a Meta-analysis |
Wang, Huai-Gao
(Department of Pathophysiology, Guangdong Medical College)
Wu, Qing-Yun (Department of Pharmacology, Guangdong Medical College) Zhou, Hui (Department of otolaryngology, Affiliated Hospital of Guangdong Medical College) Peng, Xin-Sheng (Department of Pharmacology, Guangdong Medical College) Shi, Meng-Jie (Department of Pathophysiology, Guangdong Medical College) Li, Jie-Mei (Department of Pathophysiology, Guangdong Medical College) Zhou, Yan-Fang (Department of Pathophysiology, Guangdong Medical College) |
1 | Greenblatt MS, Bennett WP, Hollstein M, et al (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res, 54, 4855-78. |
2 | Hitzenbichler F, Stoehr CG, Rogenhofer M, et al (2014). Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer. Pathobiology, 81, 53-9. DOI ScienceOn |
3 | Horikawa Y, Nadaoka J, Saito M, et al (2008). Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep, 20, 49-55. |
4 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
5 | Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107. DOI ScienceOn |
6 | Wang L, Liu Z, Jing P, et al (2014). Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol, 35, 1649-52. DOI |
7 | Wang LH, Wang X, Xu WT, et al (2014). MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis. Tumour Biol, 35, 3167-70. DOI ScienceOn |
8 | Wang M, Zhang Z, Zhu H, et al (2008). A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res, 14, 3633-40. DOI ScienceOn |
9 | Zhao E, Cui D, Yuan L, et al (2012). MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis. Mol Biol Rep, 39, 3471-7. DOI |
10 | Knowles MA (2008). Molecular pathogenesis of bladder cancer. Int J Clin Oncol, 13, 287-97. DOI ScienceOn |
11 | Kubbutat MH, Jones SN, Vousden KH (1997). Regulation of p53 stability by Mdm2. Nature, 387, 299-303. DOI ScienceOn |
12 | Levine AJ, Momand J, Finlay CA (1991). The p53 tumour suppressor gene. Nature, 351, 453-6. DOI ScienceOn |
13 | Ma Y, Bian J, Cao H (2013). MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PloS One, 8, 56918. DOI |
14 | McConkey DJ, Lee S, Choi W, et al (2010). Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol, 28, 429-40. DOI ScienceOn |
15 | Mommsen S, Aagaard J (1983). Tobacco as a risk factor in bladder cancer. Carcinogenesis, 4, 335-8. DOI ScienceOn |
16 | Olfert SM, Felknor SA, Delclos GL (2006). An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J, 99, 1256-63. DOI ScienceOn |
17 | Onat OE, Tez M, Ozcelik T, et al (2006). MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res, 26, 3473-5. |
18 | Pietsch EC, Humbey O, Murphy ME (2006). Polymorphisms in the p53 pathway. Oncogene, 25, 1602-11. DOI ScienceOn |
19 | Tian X, Tian Y, Ma P, et al (2013). Association between MDM2 SNP309 T>G and risk of gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 1925-9. 과학기술학회마을 DOI ScienceOn |
20 | Cao X, Zhang T, Zhao Z, et al (2012). MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis. DNA Cell Biol, 31, 355-9. DOI ScienceOn |
21 | Fang Z, Chen F, Wang X, et al (2013). XRCC1 Arg194Trp and Arg280His polymorphisms increase bladder cancer risk in Asian population: evidence from a meta-analysis. PLoS One, 8, e64001. DOI |
22 | Gangwar R, Mittal RD (2010). Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol, 29, 349-56. DOI ScienceOn |
23 | GLOBOCAN 2012, IARC. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. |
24 | Ma HB, Huang T, Han F, et al (2012). Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis. Asian Pac J Cancer Prev, 13, 2841-6. 과학기술학회마을 DOI ScienceOn |
25 | Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, et al (2007). Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol, 25, 285-95. DOI ScienceOn |